Meropenem/vaborbactam fixed combination for the treatment of patients with complicated urinary tract infections.
M.W McCarthy, T. J. Walsh
págs. 521-530
Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
J.A.S. García, Michael E. Percival
págs. 531-544
Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients.
M Zaid Iskandar, C. C. Lang
págs. 545-552
Notable licensing deals in the biopharma industry in the third quarter of 2017
P D'Souza
págs. 553-558
European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS) – 7th Joint Triennial Congress (October 25-28, 2017 – Paris, France).
N. Díaz
págs. 559-564
New product intros (abemaciclib mesylate, delafloxacin meglumine, copanlisib hydrochloride, darunavir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (new combination), eculizumab (new indication), ibrutinib (new indication), influenza vaccine, quadrivalent, tisagenlecleucel (first-in-class).
págs. 565-568
© 2001-2024 Fundación Dialnet · Todos los derechos reservados
Coordinado por: